Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nichi-Iko Pharmaceutical Co., Ltd.

http://www.nichiiko.co.jp/english

Latest From Nichi-Iko Pharmaceutical Co., Ltd.

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

Coronavirus COVID-19 Generic Drugs

Nichi-Iko’s Operating Profit Slumps More Than 85% As Price Revisions Bite

Japan’s Nichi-Iko saw its bottom line take a hammering in the six months to 30 September, as a number of its products had their prices cut following revisions to the National Health Insurance program.

Sales & Earnings Strategy

Japanese Firms Pursued Over Edirol Ingredient

Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.

Intellectual Property Legal Issues

Lupin CEO On ProAir Generic Site Transfer, Digital Plans

Lupin CEO Vinita Gupta shares plans to shift manufacture of albuterol and some other products to its US facilities, with a rollout of a generic to Teva’s ProAir expected soon. Enthused by Lupin’s first biosimilar introduction In Europe with etanercept and looking to up the company’s digital game, the executive says Amazon’s entry into India’s e-pharmacy space is not a near-term worry

India Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Elmed Eisai Co., Ltd
    • Nichi-Iko Medical Practice Institution Co., Ltd.
    • Yakuhan Pharmaceutical Co., Ltd.
    • Nichi-Iko Pharma Tech Co., Ltd.
    • Omega Laboratories Limited
    • Sagent Pharmaceuticals Inc.
    • Nihon Iyakuhin Kogyo Co., Ltd.
UsernamePublicRestriction

Register